Table 3 Biological Context
From: Host sequence motifs shared by HIV predict response to antiretroviral therapy
Category | Term | Count | % | p-value |
|---|---|---|---|---|
GO BP Level 5 | GO:0016310~phosphorylation | 13 | 39.39% | 5.21E-8 |
GO BP Level 5 | GO:0008219~cell death | 10 | 30.30% | 7.86E-5 |
GO BP Level 5 | GO:0006260~DNA replication | 6 | 18.18% | 9.30E-5 |
GO BP Level 5 | GO:0006915~apoptosis | 9 | 27.27% | 3.16E-4 |
GO BP Level 5 | GO:0006935~chemotaxis | 5 | 15.15% | 4.02E-4 |
GO MF Level 5 | GO:0004697~protein kinase C activity | 7 | 21.21% | 1.22E-12 |
GO MF Level 5 | GO:0004672~protein kinase activity | 11 | 33.33% | 1.75E-6 |
GO MF Level 5 | GO:0032559~adenyl ribonucleotide binding | 15 | 45.45% | 1.97E-6 |
GO MF Level 5 | GO:0003697~single-stranded DNA binding | 5 | 15.15% | 6.65E-6 |
GO MF Level 5 | GO:0004707~MAP kinase activity | 2 | 6.06% | 0.0395 |
KEGG PATHWAY | hsa04650:Natural killer cell mediated cytotoxicity | 10 | 30.30% | 8.77E-9 |
KEGG PATHWAY | hsa04664:Fc epsilon RI signaling pathway | 8 | 24.24% | 1.30E-7 |
KEGG PATHWAY | hsa04530:Tight junction | 9 | 27.27% | 3.36E-7 |
KEGG PATHWAY | hsa04370:VEGF signaling pathway | 7 | 21.21% | 1.05E-6 |
KEGG PATHWAY | hsa04912:GnRH signaling pathway | 6 | 18.18% | 1.24E-4 |
KEGG PATHWAY | hsa05223:Non-small cell lung cancer | 5 | 15.15% | 1.34E-4 |